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To the Editor: Diabetes has consistently been shown to inde-
pendently increase the risk of poor coronavirus disease-2019
(COVID-19) outcomes [1–3]. Rather than a simple additive
effect of diabetes and age-related risk, recent large studies
suggest a more complex relationship, with a disproportionate-
ly higher excess relative mortality risk in younger people with
diabetes compared with older people with diabetes [1, 3, 4].
Better understanding of the interaction between age and diabe-
tes in the context of COVID-19 will further inform the
complex prioritisation decisions around COVID-19 vaccina-
tion [5].
To explore this relationship, we triangulated the evidence
on heterogeneity of diabetes effect by age on COVID-19
mortality from large population-based and critical care-based
studies. Two UK population-based studies (OpenSAFELY
[n = 17,278,392; 8.8% with diabetes] and QCOVID [n =
6,083,102; 7.0% with diabetes]) have previously reported
adjusted age-specific hazard ratios for COVID-19-related
mortality risk associated with diabetes [1, 4]. OpenSAFELY
reported these stratified by recent HbA1c measurements as
recorded in primary care (</≥58 mmol/mol [</≥7.5%] or not
available), but not by diabetes type. QCOVID reported age-
specific hazard ratios for type 2 diabetes by sex, but did not
report age-specific values for type 1 diabetes (see electronic
supplementary material [ESM] Methods). The overall 90-day
COVID-19-re la ted mor ta l i ty ra te was 0.06% in
OpenSAFELY (study period: 1 February 2020–6 May 2020)
and the 97-day COVID-19-related mortality rate was 0.07%
in QCOVID (derivation cohort study period: 24 January
2020–30 April 2020).
Building on our previous analysis in the critical care setting
[3], we also examined adjusted age-specific hazard ratios
associated with type 2 diabetes in people with severe
COVID-19 using the COVID-19 Hospitalisation in England
Surveillance System (CHESS) cohort (n = 19,256 individuals
admitted to critical care in England; 18.3% with type 2 diabe-
tes; see ESM Methods). In this cohort, the 30-day in-hospital
mortality rate was 26.4% (see ESM Table 1 for age-stratified
mortality rates).
To aid interpretability of our findings, based on the work of
Spiegelhalter [6, 7], we translated hazard ratio estimates into
‘COVID-age’, which represents the additional years of
COVID-19 mortality risk added to an individual’s chronolog-
ical age if diabetes is present. Full details of our approach are
provided in the ESM Methods. The study was reviewed and
approved by the Warwick BSREC (BSREC 119/19-20).
The additional COVID-19 mortality risk associated with
diabetes is, in terms of COVID-age, markedly higher in youn-
ger than older people (Fig. 1). This reflects the higher relative
risk of COVID-19-related mortality associated with diabetes
in younger age groups (hazard ratios for diabetes >5 in adults
under 50 years of age in population-based studies).
Population-based and critical care-based estimates are similar,
despite differences in setting, time period and adjustments for
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confounders between studies. For a person aged 40 years with
diabetes, additional mortality risk is equivalent to around
20 years of chronological age, meaning that mortality risk is
similar to that of a 60-year-old person without diabetes. For a
person aged 70 years with diabetes, the additional mortality
risk from diabetes is equivalent to an additional 8 years of age,
so their COVID-age is 78 years (based on QCOVID data).
Clearly, considering only age and diabetes status when
assessing COVID-19-associated risks (both mortality and in
general) is an oversimplification. Multiple additional factors,
including BMI, diabetes duration, glycaemic control, diabetes
type and existing complications are known to further modify
individual COVID-19 risk [8, 9]. Whilst patient-level risk
incorporating these multiple factors can be calculated [10]
(and is preferable for informing individuals of their COVID-
19 risk), this is not practical for population-level vaccine roll-
out. The time-critical nature of population COVID-19 vacci-
nation necessitates pragmatic group-level prioritisation, which
is the approach initiated by governments thus far [11, 12].
Whilst the absolute risk of COVID-19-related mortality in
younger people with diabetes is still not as high as that of the
elderly, vaccine prioritisation approaches should not simply
consider absolute mortality risk. Younger people are dispro-
portionately impacted in terms of life years lost and are of
working age, which puts them at potentially higher risk of
exposure. These factors should be considered, alongside the
excess relative COVID-19 mortality risk in younger people
with diabetes, to ensure that they are appropriately prioritised
for vaccination.
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Fig. 1 The additional years of COVID-19 mortality risk added to an
individual’s chronological age if diabetes is present (‘COVID-age’)
compared with actual age (dotted black line) in people aged 30–90 years.
Data are from two large UK population-based studies (OpenSAFELY
[n=17,278,392] and QCOVID [n=6,083,102]) and a national database
of critical care patients in England (COVID-19 Hospitalisation in
England Surveillance System [CHESS] cohort [n=19,256]). Underlying
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